Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 10/20 | 0.41 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066932 | 0.81 | DYRK1A (0.47) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL12482954 | 0.81 | DYRK1A (0.47) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL2067982 | 0.78 | DYRK1A (0.45) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL9968614 | 0.77 | DYRK1A (0.44) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL18911173 | 0.77 | DYRK1A (0.44) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL19006101 | 0.77 | DYRK1A (0.44) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL16340202 | 0.77 | DYRK1A (0.44) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL2065715 | 0.75 | DYRK1A (0.42) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL16331313 | 0.75 | FYN (0.49) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL102246 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3181566-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-8343973-B2 | Phenoxymethyl heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012040230-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040230-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | DYRK1A 4075/4885CLK4 4562/4885MAPK14 2720/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | DYRK1A 1194/4885CLK4 2066/4885MAPK14 1658/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | DYRK1A 1817/4885CLK4 2625/4885MAPK14 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.